Champions Oncology (CSBR) Receivables (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Receivables of $20.7 million for Q2 2026, up 24.72% year-over-year from $16.6 million in Q2 2025, and up 7.81% quarter-over-quarter from $19.2 million in Q1 2026.
Champions Oncology (CSBR) Receivables (2011 - 2026) Analysis & Trends
Champions Oncology's Receivables history runs 16 years deep, the most recent figure standing at $20.7 million for Q2 2026.
- In Q2 2026, Receivables rose 24.72% year-over-year to $20.7 million; the TTM figure through Apr 2026 stood at $20.7 million (up 24.72% YoY), while the FY2026 annual figure was $21.8 million, up 23.44% from the prior year.
- Receivables for Q2 2026 stood at $20.7 million, up from $19.2 million in the prior quarter.
- The five-year high for Receivables was $22.6 million in Q1 2025, with the low at $11.7 million in Q4 2023.
- The 5-year median for Receivables is $14.6 million (2023), against an average of $15.7 million.
- The sharpest annual moves came in 2025 and 2026: Receivables surged 68.12% in 2025, then slipped 14.83% in 2026.
- Champions Oncology's Receivables stood at $13.3 million in 2022, then declined by 12.12% to $11.7 million in 2023, then surged by 54.89% to $18.1 million in 2024, then advanced by 8.82% to $19.7 million in 2025, then gained by 4.98% to $20.7 million in 2026.
- Business Quant data shows CSBR's Receivables at $20.7 million in Q2 2026, $19.2 million in Q1 2026, and $19.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 21.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 20.71 Mn |
| Jan 31, 2026 | 19.21 Mn |
| Oct 31, 2025 | 19.72 Mn |
| Jul 31, 2025 | 15.81 Mn |
| Apr 30, 2025 | 16.60 Mn |
| Jan 31, 2025 | 22.55 Mn |
| Oct 31, 2024 | 18.13 Mn |
| Jul 31, 2024 | 15.80 Mn |
| Apr 30, 2024 | 15.47 Mn |
| Jan 31, 2024 | 13.41 Mn |
| Oct 31, 2023 | 11.70 Mn |
| Jul 31, 2023 | 13.23 Mn |
| Apr 30, 2023 | 13.83 Mn |
| Jan 31, 2023 | 12.48 Mn |
| Oct 31, 2022 | 13.32 Mn |
| Jul 31, 2022 | 13.77 Mn |
| Apr 30, 2022 | 13.62 Mn |
| Jan 31, 2022 | 13.18 Mn |
| Oct 31, 2021 | 12.64 Mn |
| Jul 31, 2021 | 11.83 Mn |